Suzhou Ribo Life Science Co

Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertrigly ceridemia; RBD7022, which is in phase 2 clinical trial for the treatment of hypercho lesterolemia; RBD7007 and RBD2080 that are in Phase I clinical trial for the treatment of renal diseases; and RBD1119 for treating thrombotic diseases that is in Phase I clinical trial. The company also develops SR122 and SR126 for treating dyslipidemia; RBD3103 for treating renal diseases; RBD6096 for the treatment of thrombotic diseases; SR118 for treating metabolic diseases; RBD1016, which is in Phase II clinical trial for the treatment of CHB and CHD; RBD3133 for treating weight loss; RBD8088 for treating glioma; SR131 for treating CNS diseases; and SR111, SR112, and SR113 for the treatment of metabolic dysfunction-associated steatohepatitis. Suzhou Ribo Life Science Co., Ltd. was incorporated in 2007 and is based in Kunshan, China.

Industry

Biotechnology

Sector

Healthcare

Headquarters

CN

CEO

Liang Zicai

Listed since

Jan 9, 2026

Employees

407